

Comprehensive Oncology Limited

Unaudited Abbreviated Accounts

for the Year Ended 31 March 2016

Ballard Dale Syree Watson LLP
Chartered Accountants
11c Oakmoore Court
Kingswood Road
Hampton Lovett
Droitwich
Worcestershire
WR9 0QH

Comprehensive Oncology Limited

Contents

Abbreviated Balance Sheet	<u>1</u>
Notes to the Abbreviated Accounts	<u>2</u> to <u>3</u>

Comprehensive Oncology Limited

(Registration number: 08940397)

Abbreviated Balance Sheet as at 31 March 2016

	Note	2016 £	2015 £
Fixed assets			
Tangible assets	<u>2</u>	3,726	499
Current assets			
Debtors		8,909	5,079
Cash at bank and in hand		89,918	49,692
		<u>98,827</u>	<u>54,771</u>
Creditors: Amounts falling due within one year		(16,620)	(24,694)
Net current assets		<u>82,207</u>	<u>30,077</u>
Total assets less current liabilities		85,933	30,576
Accruals and deferred income		(1,850)	(1,850)
Net assets		<u>84,083</u>	<u>28,726</u>
Capital and reserves			
Called up share capital	<u>3</u>	100	100
Profit and loss account		83,983	28,626
Shareholders funds		<u>84,083</u>	<u>28,726</u>

For the year ending 31 March 2016 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved by the director on 21 June 2016

.....

Dr Peter Denzil Correa

The notes on pages 2 to 3 form an integral part of these financial statements.

Page 1

Comprehensive Oncology Limited

Notes to the Abbreviated Accounts for the Year Ended 31 March 2016

1 Accounting policies

Turnover

Turnover represents amounts chargeable in respect of the sale of goods and services to customers.

Revenue recognition

Revenue is recognised to the extent that the company obtains the right to consideration in exchange for its performance. Revenue is measured at the fair value of the consideration received, excluding discounts, rebates, VAT and other sales tax or duty.

Depreciation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Depreciation method and rate
Fixtures and fittings	33% reducing balance

2 Fixed assets

	Tangible assets £	Total £
Cost		
At 1 April 2015	748	748
Additions	3,793	3,793
	<hr/>	<hr/>
At 31 March 2016	4,541	4,541
	<hr/>	<hr/>
Depreciation		
At 1 April 2015	249	249
Charge for the year	566	566
	<hr/>	<hr/>
At 31 March 2016	815	815

Comprehensive Oncology Limited

Notes to the Abbreviated Accounts for the Year Ended 31 March 2016

3 Share capital

Allotted, called up and fully paid shares

	2016		2015	
	No.	£	No.	£
Allotted, issued and fully paid of £1 each	100	100	100	100

4 Control

The director is the controlling party by virtue of his controlling shareholding in the company.

Page 3

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.